Earnings Outlook For Prosperity Bancshares

Prosperity Bancshares (NYSE:PB) is set to give its latest quarterly earnings report on Wednesday, 2024-01-24. Here’s what investors…

Prosperity Bancshares (NYSE:PB) is set to give its latest quarterly earnings report on Wednesday, 2024-01-24. Here’s what investors need to know before the announcement.

Analysts estimate that Prosperity Bancshares will report an earnings per share (EPS) of $1.17.

Prosperity Bancshares bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.05, which was followed by a 4.76% increase in the share price the next day.

Here’s a look at Prosperity Bancshares’s past performance and the resulting price change:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 1.15 1.15 1.34 1.49
EPS Actual 1.20 1.21 1.37 1.51
Price Change % 4.76% -0.86% 3.4% -1.06%

eps graph

Stock Performance

Shares of Prosperity Bancshares were trading at $66.92 as of January 22. Over the last 52-week period, shares are down 13.06%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

To track all earnings releases for Prosperity Bancshares visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Why Dave & Buster’s Stock Is Up Today

UBS analyst Dennis Geiger maintained Dave & Buster's with a Neutral rating and raised the price target from $60 to $66, and Truist Securities maintained its Buy rating and raised the price target from $75 to $78 following the print. According to data from Benzinga Pro, 17.73% of available shares are being sold short which can contribute to large price moves when combined with high trading volume.

PLAY

Read More

Lifecore Biomedical Provides Update For Development Portfolio And Timing Of Delayed Filings; Anticipates Reporting Its FY24 Q1 Results In Late October Or Early November, Pending Completion Of Its Annual Audit

Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today provided an update on its delayed filings. The Company anticipates reporting

LFCR